Vaccine Biomarkers: Don't Put Cart Before Horse When Designing Studies, US FDA Advises
Executive Summary
If a sponsor wants to use a biomarker to show vaccine effectiveness, it should first explain why a clinical endpoint study is not feasible, US FDA official advises.